TNF alpha induced protein 6Genealiases: TSG-6 · TSG6
Q-omics provides the consensus-scored TNFAIP6 profile across patient tissues and cancer cell-line models. TNFAIP6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TNFAIP6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TNFAIP6 RNA expression shows 21,031 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TNFAIP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFAIP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFAIP6 survival associations across molecular data types. TNFAIP6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFAIP6 RNA expression–survival associations across cancer types. High TNFAIP6 expression shows unfavorable associations in UVM, LGG, BLCA, CESC and MESO, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TNFAIP6 RNA expression.
This table summarizes TNFAIP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TNFAIP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFAIP6 shows higher tumor expression in KIRC, HNSC, KIRP, COAD, THCA and LUAD. The KIRC box plot shows higher TNFAIP6 RNA expression in tumor versus normal tissue (log2 FC = +5.579, t-test p < 0.001).
This table shows molecular features associated with TNFAIP6 in patient tissues and cancer cell lines. In patient samples, TNFAIP6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFAIP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
